News Headline Summary

FDA is reviewing Novartis's (NOVN VX) Signifor for treatment of Cushing's disease

Update details:

- FDA advisory panel will meet on 7/11/12 to discuss drug.

Reaction details:

Novartis shares unaffected by the news, last trade at CHF 56.90

Print 14:17, 05 Nov 2012 - SMI - Source: Newswires